One study revealed that CAFs extracted from anti-VEGF resistance murine lymphoma cell line (EL4) could effectively resist the anti-VEGF therapy in otherwise sensitive murine myeloma cell line (TIB6) via platelet-derived growth factor-C (PDGF-C) mediation (Crawford et al. 2009). Here, VEGFA is linked to lymphoma.